In December 2022, the US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) issued guidance on online tracking technology to HIPAA-covered entities.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh